We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mallinckrodt to Divest Nuclear Imaging Business for $690M
Read MoreHide Full Article
Mallinckrodt plc announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.
Of the total value of the deal, approximately $574 million comprises up-front payment, $39 million covers long-term obligations and approximately $77 million consists of contingent consideration.
The Nuclear Imaging business includes a portfolio of diagnostic imaging products. Although these products are approved for use in nuclear medicine procedures in many countries, as much as two-thirds of the current annual revenues from this business are generated in the U.S. It presently employs 800 people.
The transaction is expected to close in the first half of 2017.
Note that the Nuclear Imaging business had been facing challenges for quite some time now. Hence, a divestiture was around the corner. Management is focused on reshaping the company through strategic acquisitions and non-core asset divestitures.
Keeping with this, Mallinckrodt sold its contrast media and delivery systems (CMDS) business in Nov 2015. The company has been extremely active on the acquisition front as well. Earlier this year, Mallinckrodt acquired hemostasis drugs – Recothrom Thrombin topical (recombinant), PreveLeak and Raplixa (fibrin sealant) – from The Medicines Co. in a transaction that strengthened its growing hospital portfolio. In 2015, it acquired privately held critical care company, Ikaria, in a transaction that added Inomax, a vasodilator used in conjunction with ventilatory support and other appropriate agents, to its portfolio. Meanwhile, last September, the company acquired Therakos Inc. in an attempt to broaden its footprint in hospitals.
Mallinckrodt currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) and Corcept Therapeutics Incorporated (CORT - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Mallinckrodt to Divest Nuclear Imaging Business for $690M
Mallinckrodt plc announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.
Of the total value of the deal, approximately $574 million comprises up-front payment, $39 million covers long-term obligations and approximately $77 million consists of contingent consideration.
The Nuclear Imaging business includes a portfolio of diagnostic imaging products. Although these products are approved for use in nuclear medicine procedures in many countries, as much as two-thirds of the current annual revenues from this business are generated in the U.S. It presently employs 800 people.
The transaction is expected to close in the first half of 2017.
Note that the Nuclear Imaging business had been facing challenges for quite some time now. Hence, a divestiture was around the corner. Management is focused on reshaping the company through strategic acquisitions and non-core asset divestitures.
MALLINCKRODT PL Price
MALLINCKRODT PL Price | MALLINCKRODT PL Quote
Keeping with this, Mallinckrodt sold its contrast media and delivery systems (CMDS) business in Nov 2015. The company has been extremely active on the acquisition front as well. Earlier this year, Mallinckrodt acquired hemostasis drugs – Recothrom Thrombin topical (recombinant), PreveLeak and Raplixa (fibrin sealant) – from The Medicines Co. in a transaction that strengthened its growing hospital portfolio. In 2015, it acquired privately held critical care company, Ikaria, in a transaction that added Inomax, a vasodilator used in conjunction with ventilatory support and other appropriate agents, to its portfolio. Meanwhile, last September, the company acquired Therakos Inc. in an attempt to broaden its footprint in hospitals.
Mallinckrodt currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) and Corcept Therapeutics Incorporated (CORT - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>